Wilson Sonsini Goodrich & Rosati advised Kumquat Biosciences on the transaction. Kumquat Biosciences, a leader in translating breakthrough science into first-in-class therapeutics, announced a strategic and...
Kumquat Biosciences’ $1.2 Billion Collaboration and License Agreement with Takeda
Kumquat Biosciences’ $1.2 Billion Collaboration and License Agreement with Takeda
Wilson Sonsini Goodrich & Rosati advised Kumquat Biosciences on the transaction. Kumquat Biosciences, a leader in translating breakthrough science into first-in-class therapeutics, announced a strategic and...
Floreo’s Acquisition of Autism Eyes
Wilson Sonsini Goodrich & Rosati advised Floreo on the transaction. Floreo, a leading behavioral therapy virtual reality (VR) company, announced it has acquired Autism Eyes, an...
Halia Therapeutics’ $30 Milliion Series C Financing Round
Wilson Sonsini Goodrich & Rosati represented Halia Therapeutics in the transaction. Halia Therapeutics announced it raised $30 million in Series C financing round led by Todd Pedersen, with continued...
Foresight Diagnostics’ Partnership with Allogene Therapeutics
Wilson Sonsini Goodrich & Rosati advised Foresight Diagnostics on the transaction. Allogene Therapeutics Inc. (Nasdaq: ALLO) and Foresight Diagnostics, announced a strategic partnership to develop a minimal residual...
Unilever’s Acquisition of K18
Wilson Sonsini Goodrich & Rosati is advising K18 on the transaction. Unilever announced it signed an agreement to acquire premium biotech haircare brand K18. Founded in 2020...
Absci’s Collaboration with Astrazeneca
Wilson Sonsini Goodrich & Rosati advised Absci on the transaction. Absci Corporation (Nasdaq: ABSI) announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed...
Arcellx’s Expansion of Partnership with Kite
Wilson Sonsini Goodrich & Rosati is advising Arcellx on the transaction. Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD) announced that they have...
LENZ Therapeutics’ Merger with Graphite Bio
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
Assembly Biosciences’ Partnership with Gilead Sciences
Wilson Sonsini Goodrich & Rosati advised Assembly Bio on the transaction, and Ropes & Gray advised Gilead Sciences, Inc. Assembly Biosciences (Nasdaq: ASMB) and Gilead Sciences (Nasdaq:...
Pacific Biosciences’ Acquisition of Apton Biosystems
Wilson Sonsini Goodrich & Rosati is representing Pacific Biosciences, and Fenwick & West is representing Apton Biosystems in the transaction. 8Pacific Biosciences of California (NASDAQ: PACB) (PacBio) announced...
Cognito Therapeutics’ $73 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Cognito on the transaction. Neurotechnology company Cognito Therapeutics announced a $73 million Series B financing round. The financing was led...